July 16, 2018
Urovant Chief Executive Keith Katkin
Stories this photo appears in:
22,000-sq.-ft. Lease for Drug Company With 2018 IPO
Urovant Sciences Ltd., an Irvine-based clinical-stage biopharma company that started operations in 2016 and went public last September, is about to get a much larger home near the University of California-Irvine.
Irvine-based Urovant Sciences Inc. is seeking $150 million via the public markets to extend clinical trials of therapies to treat urologic conditions.